Despite Recent Changes in Plans, Big Pharma Maintains RNAi Partnerships
December 09, 2010
Despite Recent Changes in Plans, Big Pharma Maintains RNAi Partnerships
Among these is a deal between Dicerna Pharmaceuticals and Japan's Kyowa Hakko Kirin, which announced this week that they have expanded their drug-development partnership to include work in immunologic and inflammatory diseases.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space
July 22, 2010 / Gene Silencing News - Lundbeck, Debiopharm Join List of Pharmas Looking to RNAi
February 3, 2011 / Gene Silencing News - For Some RNAi Rx Shops, Industry Deals with Bigger Players are Par for the Course
August 20, 2009 / Gene Silencing News - RNAi Field Looks to Late-Stage Clinical Data, Approvals to Regain Pharma Interest
January 3, 2013 / Gene Silencing News - In 2011, miRNAs Move Beyond 'Scientific Curiosity' as Big Pharma Externalizes Oligo Drug Development
January 5, 2012 / Gene Silencing News